COMPLETION OF ROUND A FUNDING

INGLEWOOD, CALIFORNIA, June 11, 2008 – PKC today announced the completion of Round A funding in the gross amount of $2 Million. PKC is a life science company with core technology around the design and development of innovative, implantable smart drug delivery device candidates it is hoped will be capable of directly delivering a drug to targeted tissues and organs anywhere in the body. PKC is currently in the early development phase of an implantable chemotherapy pump candidate that will be designed to treat malignant brain gliomas. Patients diagnosed with a glioblastoma multiforme, the most malignant type of glioma, currently have average life expectancies of 12-15 months.

If successfully developed and provided that regulatory approval is obtained, the PKC pump candidate will enable these patients to have direct delivery of their chemotherapy into the cancer, bypassing the blood-brain barrier. This innovative technology, once fully developed and approved for use, will present a new treatment paradigm for malignant brain tumors.

Phase One development will begin in the Fall in collaboration with the USC Department of Neurosurgery and Pathology under the direction of noted Neurosurgeon Thomas C. Chen, MD, Ph.D.

For additional information, please contact:
Daniel Saks Senior
Vice President, Corporate Affairs
Pharmaco-Kinesis Corporation
(310) 734-4447